Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
Frequently asked questions
What sector does Arctic Bioscience AS (ABS) operate in?
Arctic Bioscience AS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Arctic Bioscience AS (ABS) current stock price?
As of the latest data, Arctic Bioscience AS stock price is NOK 3.00, with a previous close of NOK 3.00.
What is Arctic Bioscience AS (ABS) current market capitalization?
Arctic Bioscience AS market cap is approximately 80.87 million.
What is Arctic Bioscience AS (ABS) Earnings Per Share (EPS)?
The trailing EPS is -NOK 1.52.
Does Arctic Bioscience AS (ABS) pay dividends?
No. Arctic Bioscience AS does not pay a dividend.
What is Arctic Bioscience AS (ABS) beta (volatility) score?
Arctic Bioscience AS has a beta of 1.068, meaning its volatility is roughly in line with the market.
